Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study

Basit Öğe Kaydı
dc.authoridmert, kadir ugur/0000-0002-1331-5365
dc.contributor.authorOzlek, Bulent
dc.contributor.authorOzlek, Eda
dc.contributor.authorAgus, Hicaz Zencirkiran
dc.contributor.authorTekinalp, Mehmet
dc.contributor.authorKahraman, Serkan
dc.contributor.authorCil, Cem
dc.contributor.authorCelik, Oguzhan
dc.date.accessioned2025-01-21T16:43:19Z
dc.date.available2025-01-21T16:43:19Z
dc.date.issued2019
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground: To determine and compare the demographic characteristics, clinical profile and management of patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) in a Turkish cohort. Methods: The APOLLON trial (A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejection fractiON) is an observational and multicenter study conducted in Turkey. Consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had HFmrEF or HFpEF were included (NCT326114). Results: The study population included 1065 (mean age of 67.1 +/- 10.6 years, 54% women) patients from 12 sites in Turkey. Among participants, 246 (23.1%) had HFmrEF and 819 (76.9%) had HFpEF. Compared to patients with HFpEF, those with HFmrEF were more likely to be male (57.7 vs 42.2%; p < 0.001), had higher N-terminal pro-B-type natriuretic peptide levels (853 vs 528 pg/ml, p < 0.001), were more likely to have ECG abnormalities (72.4 vs 53.5%, p < 0.001) and hospitalization history for heart failure (28 vs 18.6%; p = 0.002). HFmrEF patients were more likely to use beta-blockers (69.9 vs 55.2%, p < 0.001), aldosterone receptor antagonists (24 vs 14.7%, p = 0.001), statins (37 vs 23%, p < .001), and loop diuretics (39.8 vs 30.5%, p = 0.006) compared to patients with HFpEF. Conclusions: The results of APOLLON study support that the basic characteristics and etiology of HFmrEF are significantly different from HFpEF. This registry also showed that the patients with HFmrEF and HFpEF were younger but undertreated in Turkey compared to patients in western countries.
dc.identifier.doi10.1016/j.ejim.2018.11.001
dc.identifier.endpage95
dc.identifier.issn0953-6205
dc.identifier.issn1879-0828
dc.identifier.pmid30446354
dc.identifier.startpage88
dc.identifier.urihttps://doi.org/10.1016/j.ejim.2018.11.001
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25241
dc.identifier.volume61
dc.identifier.wosWOS:000459940500024
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Bv
dc.relation.ispartofEuropean Journal of Internal Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectClinic profile; Epidemiology; Heart failure with mid-range ejection fraction; Heart failure with preserved ejection fraction
dc.titlePatients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu